US 12,440,619 B2
Microplegia delivery system
Carmen Joseph Leone, Chelsea, MI (US); and Paul Thomas Kotnik, Commerce Township, MI (US)
Assigned to Terumo Cardiovascular Systems Corporation, Ann Arbor, MI (US)
Filed by Terumo Cardiovascular Systems Corporation, Ann Arbor, MI (US)
Filed on Aug. 13, 2020, as Appl. No. 16/992,795.
Prior Publication US 2022/0047802 A1, Feb. 17, 2022
Int. Cl. A61M 1/36 (2006.01); A61M 5/145 (2006.01); A61M 60/113 (2021.01); A61M 60/50 (2021.01); A61M 60/205 (2021.01)
CPC A61M 5/1452 (2013.01) [A61M 1/3623 (2022.05); A61M 1/3667 (2014.02); A61M 60/113 (2021.01); A61M 60/50 (2021.01); A61M 1/3626 (2013.01); A61M 60/205 (2021.01); A61M 2202/047 (2013.01); A61M 2205/3368 (2013.01); A61M 2205/52 (2013.01)] 20 Claims
OG exemplary drawing
 
1. A heart/lung bypass machine system comprising:
a heart/lung machine comprising:
an arterial blood pump; and
a cardioplegia blood pump;
a first cardioplegia agent syringe pump configured to inject a first cardioplegia agent at a first location along a blood/cardioplegia supply line;
a second cardioplegia agent syringe pump configured to inject a second cardioplegia agent at a second location along the blood/cardioplegia supply line, wherein the first and second locations are longitudinally spaced apart from each other; and
a controller comprising a hardware processor and computer memory, the controller in electrical signal communication with the cardioplegia blood pump and the first and second cardioplegia agent syringe pumps,
wherein the controller is configured to modulate operational speeds of the first and second cardioplegia agent syringe pumps based on an actual speed of the cardioplegia blood pump and based on a current surgery phase of at least three different phases of surgery,
wherein the at least three different phases of surgery comprise: (i) an induction dose phase, (ii) a maintenance dose phase, and (iii) a reperfusion or reanimation dose phase,
wherein the controller is configured to receive user inputs that correlate the operational speeds of the first and second cardioplegia agent syringe pumps to the actual speed of the cardioplegia blood pump,
wherein the user inputs are percentages of the actual speed of the cardioplegia blood pump,
wherein the controller is configured to issue a time-based reminder to collect a blood sample for an activated clotting time (“ACT”) lab test and to allow for entry of results of the ACT lab test, and
wherein the controller is configured to suggest a dose adjustment based on: (i) the results of the ACT lab test, (ii) a user-established ACT target value, and (iii) one or more patient parameters.